During normal aging and pathological aging like Alzheimer's disease appear olfactory deficits. These deficits occur very early in Alzheimer's disease and could be among the first signs of the disease. Thus, the definition, comparison of olfactory trouble appearing in normal aging versus Alzheimer's disease and their cellular correlates is a crucial step toward comprehension of the disease. The first study was aimed at clarifying olfactory function in aging and it's plasticity in normal mice. Aging appears as a very complex process, touching heterogenatly olfactory components. The major sign of aging is the lack of plasticity of olfactory performances, neurogenic processes and noradrenergic system in response to an olfactory enrichment. Our datas show that olfactory memory and it's modulation by olfactory enrichment is more sensible to aging than olfactory discrimination. Despite the strong impairment of neurogenesis in aging, and regardless to it's major role in olfactory processes in young animals, basal olfactory performances (easy discrimination and very short term memory) remains intact in aged animals. We also show that olfactory neurogenesis is impaired in a biphasic way during aging (first, reduction of proliferation, and then in senescent mice, impairment of differentiation and survival in the olfactory bulb). Noradrenergic system plasticity persists in middle aged animals, contrarily to neurogenesis which does not respond to olfactory enrichment. Thus, this work gives us the background necessary to compare olfactory deficits in normal and pathological aging. Our second study confirms that olfactory troubles occurs early in APP/PS1 mice, our Alzheimer's disease model, and confirms the implication of noradrenergic deficits. A chronic depletion in noradrenalin produced by treatments with DSP4 aggravates amyloïd deposition and olfactory deficits in our mice. These datas provide a strong support to the use of olfactory modality to study early signs of the disease, and to combine noradrenergic depletion to reproduce clinical and physiopatholocical signs of Alzheimer's disease in human.
